Search Results for: immunosuppression

June 14, 2026

Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study.

Melanoma Literature

Publication date: Jun 12, 2026 Immune checkpoint inhibitor-induced immune-related adverse events (irAEs) can be steroid-refractory (sr) or steroid-dependent (sd), requiring second-line therapy. Evidence guiding optimal management of sr/sd-irAEs while preserving ... Read more

April 23, 2026

A novel enterotype enriched with respiratory super-dominant pathobionts is associated with immunosuppression in pulmonary tuberculosis patients.

Tuberculosis Literature

Publication date: Apr 20, 2026 Perturbations of the gut microbiota in pulmonary tuberculosis (PTB) patients, often antibiotic-induced, are frequently observed; however, the defining features of this dysbiosis and its relationship ... Read more

April 3, 2026

A Case of Rapidly Progressive Interstitial Lung Disease with Coexisting Anti-MDA5 and Anti-OJ Antibodies Successfully Treated with Intensive Immunosuppression and Plasma Exchange.

Melanoma Literature

Publication date: Mar 31, 2026 Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis is frequently complicated by rapidly progressive interstitial lung disease, whereas anti-aminoacyl-tRNA synthetase (ARS) antibody-positive interstitial lung disease typically ... Read more

March 17, 2026

Melanoma Risk in 12,205 Kidney Transplant Recipients Receiving Calcineurin Inhibitor-Based Immunosuppression: A Nationwide Analysis of Polish National Health Fund Data (2010-2022).

Melanoma Literature

Publication date: Feb 16, 2026 Background: Numerous studies have demonstrated the impact of post-transplant immunosuppressive therapy on cancer development, particularly in the skin. Despite the growing number of observations, there ... Read more

January 30, 2026

Recurrent Urinary Tract Infections in a Patient with Diffuse Large B-Cell Lymphoma and Severe COVID-19: A Single Case of Suspected Immunosuppression Where Antibacterial Therapy Was Not Enough.

Coronavirus Literature

Publication date: Jan 03, 2026 Background: Non-Hodgkin lymphoma (NHL) is a malignancy of the immune system that includes several subtypes, most commonly diffuse large B-cell lymphoma and follicular lymphoma. Its ... Read more

January 30, 2026

Infectious Disease Screening and Vaccinations Guidelines for Patients Initiating Immunosuppression for Dermatologic Conditions: A Multidisciplinary Design and Quality Improvement Initiative.

Tuberculosis Literature

Publication date: Jan 28, 2026 Through a multidisciplinary quality improvement initiative, the Pre-Immunosuppression (Pre-IS) Clinic was created at a tertiary referral institution to ensure appropriate vaccination and infectious disease screening ... Read more

January 24, 2026

[Positive interferon-gamma release assay and immunosuppression: guideline-based diagnosis and treatment of tuberculosis infection].

Tuberculosis Literature

Publication date: Jan 19, 2026 With the growing use of immunosuppressive therapies, clinicians are increasingly faced with the question of how to manage positive interferon-gamma release assays (IGRA). A tuberculosis ... Read more

December 27, 2025

Impact of maintenance immunosuppression regimen on anti-SARS-CoV-2 antibody and cellular kinetics in kidney transplant recipients receiving ChAdOx1 as primary vaccination.

Coronavirus Literature

Publication date: Dec 24, 2025 Kidney Transplant Recipients (KTRs) face increased COVID-19 risks due to immunosuppression, which may affect vaccine response. This study evaluates the impact of Mycophenolate Sodium (MPS) ... Read more

December 20, 2025

Sialic Acid-Modified Nanoparticles in Combination Therapy with 5-Carboxy-8-hydroxyquinoline: Dual Effects of Intrinsic Blockade of Cellular Escape and Extrinsic Relief of Immunosuppression.

Melanoma Literature

Publication date: Dec 18, 2025 Epigenetic homeostasis is integral to the development of malignant tumors. Combining epigenetic drugs with chemotherapy is a promising strategy to overcome the challenges in treating ... Read more

December 20, 2025

Whole genome sequencing confirms reactivation of Tuberculosis five years after initial infection despite adequate preventative therapy in a patient with profound immunosuppression.

Tuberculosis Literature

Publication date: Dec 17, 2025 Tuberculosis infection (TBI) can persist for years, with reactivation risk markedly increased by profound immunosuppression. Whole-genome sequencing (WGS) can definitively distinguish reactivation from reinfection, offering ... Read more